Bibliographic information
GuidelineWHO guidelines for malaria, 25 November 2022.
Year of Publication2022
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
Originally developed
Artesunate-pyronaridine for uncomplicated malaria: Artesunate-pyronaridine (ASPY) is recommended as an artemisinin-based combination therapy option for the treatment of uncomplicated P. falciparum malaria.
Recommended in favor
Strong
Certainty of evidence
Low
Notes and Remarks
Remarks
- ASPY should be avoided by individuals with known liver disease (clinically apparent liver disease) because ASPY is associated with liver transaminitis.
- Pharmacovigilance should be strengthened where ASPY is used for the treatment of malaria.
Practical Info As with the deployment of any new malaria treatment, pharmacovigilance and resistance surveillance systems should be strengthened.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
WHO guidelines for malaria, 16 October 2023.
Year2023
InstitutionWorld Health Organization
Guideline
WHO Guidelines for malaria, 14 March 2023
Year2023
InstitutionWHO
Guideline
WHO guidelines for malaria, 30 November 2024.
Year2024
InstitutionWHO